Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
A clinical-stage biotech company developing precision oncology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug combo targets tough cancers with RAS mutation
Disease control OngoingThis early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…
Phase 1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise for Tough-to-Treat skin cancer
Disease control OngoingThis study tests a new two-drug combination (naporafenib + trametinib) in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if the combo works better than standard treatments at slowing cancer growth and extending life. About 78 adults wi…
Phase 3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC